Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists


1464 67th Street
Emeryville, CA 94608
Website Company Summary Management Team

CEO: Sri Kosuri (7/31/2019)
President/COO/Operations: Michelle Wong (10/31/2020) ; Ramsey Homsany (6/30/2017)
Technology: Dean Richard (12/31/2021)

Outside board: (May no longer be on the board) Mark Murcko (Dewpoint Therapeutics Chief Scientific Officer)

Business description: Octant Bio is a next-generation therapeutics company integrating novel and scaled experimental technologies (multiplexed measurements and high-throughput synthetic chemistry) with computation to solve complex challenges in drug discovery. Octant engineers drugs with novel mechanisms of actions guided by extensive proprietary datasets in engineered human cells that unlock insights between genomes, drug candidates, biochemical function, and disease phenotypes. The Octant platform uses synthetic biology, high throughput multiplexed assays, synthetic chemistry, and computation to engineer and interrogate drugs, proteins, and cellular pathways at unprecedented scales. For more information visit

Rounds: 5
Recent Fundings: Apr 2022   May 2020
Capital raised: 115.0M
Last Round: 80.0M
Ownership: Private  
VCs include: Andreessen Horowitz ;  Allen & Co.;  Catalio Capital Management;  50 Years VC
Corporate investors: Bristol Myers Squibb

Last Tweets


Last Mentions

Record updated: Apr 2022
Sector: Biotech
Year Founded: 2017
Headcount: 51-75 as of Apr 2022
Rounds: 5
Recent Fundings: Apr 2022   May 2020
Capital Raised: 115.0M
Last Round: 80.0M
Ownership: Private